

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

031676.0263

U.S. APPLICATION NO. 09/889795

To Be Assigned

INTERNATIONAL APPLICATION NO.
PCT/US00/01350INTERNATIONAL FILING DATE
January 22, 2000PRIORITY DATE CLAIMED
January 22, 1999

TITLE OF INVENTION

SIMPLE METHOD FOR LABELED CONFIDENTIAL PRODUCTION

APPLICANT(S) FOR DO/EO/US

John P. MORSEMAN and Xiangfei ZENG

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included
13. ☐ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

Unexecuted Declaration And Power Of Attorney For Patent Application

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.7)

INTERNATIONAL APPLICATION NO

ATTORNEY'S DOCKET NUMBER

To Be Assigned

09/889795

PCT/US00/01350

029218.0004

17. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1)-(5)):**

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2) paid to USPTO
and International Search Report not prepared by the EPO or JPO \$1000.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO..... \$860.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but
international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)
but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$690.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

CALCULATIONS PTO USE ONLY

\$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =**\$100.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	-20 =		x \$18.00	\$
Independent claims	-3 =		x \$80.00	\$

MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$270.00 \$

TOTAL OF ABOVE CALCULATIONS =**\$100.00**

Reduction of ½ for filing by small entity, if applicable. A small Entity Statement
must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

\$ 0.00

SUBTOTAL =**\$100.00**

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE =**\$100.00**

Fee for recording the enclose assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$

TOTAL FEES ENCLOSED =**\$100.00****Amount to be
refunded:**

\$

charged:

\$

- a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 50-1640 in the amount of \$100.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment
To Deposit Account No. 50-1640 A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b))
must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Laurence H. Posorske
Brobeck, Phleger & Harrison LLP
1333 H Street, N.W.
Suite 800
Washington, DC 20005
(202) 220-6000 (telephone)
(202) 220-5200 (facsimile)

SIGNATURE

Laurence H. Posorske

NAME

34,698

REGISTRATION NUMBER

SIMPLE METHOD FOR LABELED CONJUGATE PRODUCTION

BACKGROUND OF THE INVENTION

5 Field of the Invention

This invention relates to the attachment of detectable labels to molecules containing free amino groups (e.g., proteins, nucleic acids and amino sugars), the molecules having specific binding sites thereby providing a method of directing the label to the moiety specifically bound by the labeled molecule.

10 Review of Related Art

N-hydroxysulfosuccinimide (NHS) esters provide one of the most common activation chemistries for creating reactive acylating agents. Homobifunctional NHS esters were first introduced as reactive cross-linking agents in the early 1970's and are widely available commercially. [Bragg, P., & Hou, C. (1975), "Subunit composition, function and spatial arrangement on the Ca^{2+} and Mg^{2+} activated adenosine triphosphatases of *Escherichia coli* and *Salmonella typhimurium*," *Eur. J. Biochem.*, **106**, 495-503, Lomant, A. & Fairbanks, G. (1976) *J. Mol. Biol.*, **104**, 243-261.] NHS esters are routinely used to conjugate proteins to each other via heterobifunctional cross-linking agents (e.g. see all of Pierce Chemicals "Double Agents" that have an NHS side; Muramoa K, Kamiya H (1988) "Preparation and characterization of a cleavable photoactivable heterobifunctional fluorescent reagent for proteins." *Agric. Biol. Chem.* **52**, 547-554) or to dyes (such as acridinium; Zomer G., Van den Berg R.H., Jansen E.H.J.M. (1988) "Optimal labelling of proteins with acridinium ester" *Anal. Chim. Acta*, **205**, 267-271.

25 N-hydroxysuccinimide (NHS) chemistry

A NHS ester is formed by the reaction of a carboxylate with NHS in the presence of a carbodiimide. To prepare a stable ester, the reaction must be done in non-aqueous environments, otherwise it will degrade with non-productive reactions; aqueously prepared esters are unstable and breakdown in a matter of hours under the best of conditions. The NHS ester- or sulfo-NHS ester-containing reactant reacts with a nucleophile to form an acylated product with the release of NHS or sulfo-NHS leaving group. The reaction is non-productive with imidazolyl ring nitrogens, sulfhydryl or hydroxyl groups, forming aqueously degraded ester or thioester bonds.

Reactions with primary and secondary amines create stable amide and imide linkages, respectively.

In proteins these reagents principally react with alpha amines at the N-terminals and the epsilon amines of lysine side chains. It is possible to create NHS esters *in situ* to react immediately with target molecules in aqueous media (Staros, J., Wright, R. & Swingel, D. (1986), *Anal. Biochem.*, **156**, 220-222; Staros, J. (1982), *Biochemistry* **21**, 3950-3955). NHS esters have a half-life in aqueous environments at pH 7 on the order of several hours (4-5 hours at 0°C pH 7.0; Lomant, A. & Fairbanks, G. (1976), *J. Mol. Biol.*, **104**, 243-261).

Carbodiimides are zero length cross-linkers that mediate the formation of an amide or phosphoramidate linkage between a carboxylate and an amine, or a phosphate and an amine, respectively. (Chu, B., Kramer, F. & Orgel, L. (1986), "Synthesis of an amplifiable reporter RNA for bioassays," *Nucleic Acids Research*, **14**, 5591-5603. Hoare, D. & Koshland, D.E. (1966) *J. Am. Chem. Soc.*, **88**, 2057.) They react with carboxylic acids to form highly reactive O-acylisourea compounds that are very short lived but react with nucleophiles to form an amide bond. There are several competing and non-productive reactions, such as with water to regenerate the carboxylate group. This reaction works effectively between pH 4.5 and 7.5. Molecules with a phosphate group such as the 5' phosphate on oligonucleotides can also react with amine-containing groups by using the carbodiimide reaction.

DCCD (a carbodiimide) and NHS have been used to activate a microplate surface, which was then washed and protein added to the well to facilitate covalent attachment of the protein to the plate. (Dagenais P., Desprez B., Altert J., Escher E. (1994), *Anal. Biochem.*, **222**, 149-155)

A method for use of EDAC (a carbodiimide) and sulfo-NHS is summarized in Hermanson, G.T., *Bioconjugate Techniques*, Academic Press, New York, London, 1966.

A protein/label complex has been made into a NHS derivative such that when it bonded to the protein transporter it would complex there and allow visualization of the position of the transporter. This is basically an activated protein/dye complex that has an active NHS on it. (Fan J., Pope L.E., Vitols K.S., Huennekens F.M.

(1991), "Affinity labeling of folate transport protein with the N-hydroxysuccinimide ester of the g isomer of fluorescein-methotrexate." *Biochem.*, **30**, 4573-4580]. NHS activated dyes are also sold on a commercial basis (e.g., see the activated Cyanine dyes sold by Amersham Pharmacia Biotech, such as FluoroLink™Cy5™ or Fluorolink™Cy5.5™).

A NHS ester of 4-hydroxytestosterone-4-hemiglutarate has been made by treatment with carbodiimide and NHS. This was mixed with horse-radish peroxidase (HRP) or β -galactosidase to make a 4HT-4-HG that was enzyme labeled. The enzyme labeled hydroxytestosterone was used for tracer studies (Hosada H., Karube T., Kobayashi N., Nambara T. (1985), "Enzyme labeling of steroids by the N-succinimidyl ester method. Preparation of horse-radish peroxidase-labelled antigen for use in enzyme immunoassay." *Chem. Pharm. Bull.*, **33**, 249-255).

SUMMARY OF THE INVENTION

The present invention is directed to simplified methods for coupling labels to particular target moieties. Such coupling is usually accomplished by activating the label, the target moiety, or both with highly reactive activating chemicals. The usual coupling protocols are problematic because the activating chemicals are prone to uncontrolled reactions which produce unwanted side-products, or a too rapid reaction resulting in dissipation of the activating chemicals without the desired coupling. Coupling reactions according to the present invention use temporal spacing of the reactants through phase change (e.g., by rapid freezing) to control the initiation and termination of reaction instead of physical spacing of the traditional method.

For example, the technique of generating NHS esters *in situ* (with no freeze-drying, just adding in reagents) is mentioned in *Bioconjugate Techniques*. This invention uses the same chemistry and the same idea of getting a label bound to another molecule, but the difference is the easy-to-use format (i.e., the "one tube format"). In this method, all reactants are prepared separately then combined in such a way that they do not react with each other until the targeted compound is added to activate the cross-linking chemicals. One such format is done by sequentially flash freezing aqueous solutions of the reactants then freeze-drying them together as a unit

(e.g., in a microcentrifuge tube). In another format of this invention, freeze-dried or otherwise dried components are prepared separately and then combined in a dry form or in a spatially separate format (e.g., in the top of a microcentrifuge tube that is sectioned into separate parts), such that the water soluble components are not in
5 condition to react with each other until addition of the compound to be labeled (in aqueous form).

This invention provides an improved method of linking labels to specific binding moieties (e.g., moieties that are useful for selecting analytical targets) using N-hydroxysuccinimide (NHS) chemistry. In particular, the invention provides for the
10 separation and stabilization of the active components achieved through sequential or separate freezing in the appropriate buffers (essentially spatial or temporal separation of components prior to utilization).

In another mode, this invention provides a kit comprising NHS, a water soluble carbodiimide (e.g., EDAC) and a label containing an amine or carboxyl moiety, these
15 components being in dry form suitable for rehydration at a pH around 7 in which all components have sufficient activity for activation and cross-linkage.

While phycobiliproteins have been considered complicated to conjugate, this invention provides a method for rapidly and easily making stable phycobiliprotein conjugates to specific target binding proteins. SMCC and SPDP pre-activated
20 phycobiliproteins have been available in several formulations. However, this invention provides a simpler method for making conjugates in that it requires fewer steps and is more rapid. In fact, this invention allows a researcher to easily label whatever specific binding molecule they would like with a carboxyl-containing label (e.g., phycobiliprotein, enzyme, PBXL™, etc.) This invention provides for kits to
25 make a conjugate, so that the person using the kit does not have to be an expert at protein conjugation to obtain useable conjugates at the end of the process.

BRIEF DESCRIPTION OF THE FIGURE

Figure 1 a schematic representation showing the steps involved in one embodiment of the method of this invention.

30 Figure 2 is a bar graph showing an example of a time course used to optimize the time for addition of the conjugal partner.

Figure 3 shows biotin dose response curves generated with activated dyes at three time points.

DETAILED DESCRIPTION OF THE INVENTION

The method of this invention allows a person to add a target moiety to be
5 labeled (e.g., a protein provided in a buffered solution) to a dry powder containing a detectable label (such as a phycobiliprotein, enzyme, protein or PBXL™ phycobilisome dye), buffer, NHS and carbodiimide, such that, once the dry powder is hydrated, a reactive NHS ester is created that links the detectable label to the target protein in a single step. The labeled targeting moiety can either be used directly as a
10 tracer (before or after quenching) or further purified to remove unbound dye and quenching reagent, thus providing a highly purified labeled compound.

In one embodiment, the invention provides a kit including a reaction vessel (e.g., a microcentrifuge tube) containing freeze-dried EDAC (the carbodiimide), a labeling moiety (e.g., phycobiliprotein, phycobilisome or other), and NHS. These
15 components are not yet reacted with each other, but were added and frozen in a sequential fashion in their own optimal buffers to maintain the stability of each component (since EDAC and NHS are stable at different pHs). On rehydration at a pH straddling the optima of these reagents, an environment conducive to completing the reaction is created to make useable conjugate (even though the environment is
20 not optimal for either the carbodiimide or the NHS).

This same format can be used for other types of cross-linking agents that require the target molecules to be first modified prior to use, if suitable reaction conditions, including proper pH ranges, are utilized for the particular chemistries being applied. For example, simple cross-linking of a protein of interest to a label
25 may be accomplished with the use of SMCC (succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate) or any of its derivatives and reductants such as dithiothreitol (DTT) or β -mercaptoethanol. These chemicals are frozen sequentially then freeze-dried. The freeze-dried materials are then rehydrated with the protein to be conjugated dissolved in buffer. This activates the materials and, upon removal of
30 the reductant through desalting or dialysis, allows them to be cross-linked to each other. Careful coordination of the protein ratios is necessary for optimal conjugates.

Sequential additions of buffer and target compound could improve the resulting product. This embodiment of the present invention also includes a kit where materials (protein, oligonucleotide probes etc.) are sequentially frozen within a matrix to which the desired attachment partner (target moiety) is added and subsequently reduced while allowing the reductant to be slowly removed, thereby driving the conjugation reaction and resulting in defined conjugates of desired and specific molar ratios. Such a matrix could be as simple as a high molecular weight dialysis tubing containing the reductant and the activated protein, or as complex as a reaction vessel that allows for slow spatial separation of reductants through gel filtration (i.e., desalting) or chemical/thermal inactivation.

Advantages of this method are that it is simple and provides a way for a researcher who may be skeptical of doing his or her own conjugation to have rapid success. Carried to its logical conclusion, it is possible to balance the ratios such that little or no quench would be needed and one can mix, incubate, then use the label directly. Alternatively, the reacted conjugate may be purified over a gel permeation column or other type of separation step to obtain highly purified conjugate.

Summary of Experimental Work

The present invention was developed from experimental work carried out in an effort to find a stable NHS ester or other functional reactive cross-linking agent for attachment of proteins, specifically labels, to other proteins and nucleic acids, with the goal of making it as user friendly as possible. In particular it was desired to provide an easy, one-step method for the conjugation of two proteins. Several experimental approaches were undertaken.

First, liquid NHS ester conjugates were made between streptavidin (SA) and various detectable labels, allophycocyanin (APC), stabilized phycobilisomes (PBXL-3), or phycoerythrin (PE), to determine the suitable conditions and ratios for adequate coupling. Since the NHS ester has a relatively short half life in near neutral conditions due to hydrolysis of the ester, the long term stability of the active NHS ester cross-linked to protein was found to be not conducive to a product that might need a shelf life of at least 6 months.

The next approach was to make the same active NHS ester protein complex using basically the same protocol with the addition of trehalose to enhance the stability of the phycobiliprotein to freezing and then immersing the whole complex in liquid nitrogen until thoroughly frozen, followed by freeze-drying of the whole complex. The freeze-dried complex was then resuspended in a streptavidin solution, and the resulting conjugate was compared against the conjugate made in a liquid format. The results clearly show a substantial loss in absolute binding capacity by the freeze-dried complex. The freeze-dried active NHS ester protein complex never outperformed the liquid complex.

As an alternative to trying to maintain a stable complex for long periods of time, the inventors investigated a protocol in which the complex was not formed until they were ready to couple the detectable label and SA together. Materials were added sequentially and frozen at each addition, first the label, then the EDAC and finally the sulfo-NHS. However, the order of this addition is of little consequence since the reagents are separated by freezing. Almost instantaneous freezing of the layers and extremely cold temperature essentially rendered the materials inert with respect to each other. The frozen compositions were then freeze-dried. Conjugates were formed when aqueous protein solutions were added to the freeze-dried powder. The resulting conjugates act very similarly to their liquid-formed counterparts, with the ability to generate similar signal when run on a BSA-Biotin microplate assay.

Producing NHS activated pigments

The invention provides these benefits by putting the three ingredients (labeling moiety, NHS, and carbodiimide) together without reacting with each other until desired. Typically this is accomplished by a sequential addition of reagents and rapid freezing, followed by a freeze-drying step, such as that shown in Figure 1. This could also be achieved by freeze-drying (or otherwise drying) each component separately and making each into homogeneous powders that could be mixed in the proper ratios as a bulk reagent under moisture-free conditions

Types of labels –

Suitable labels are detectable moieties that have free carboxyl groups. Preferably the label moiety does not have free amines, but the concentration of label must be adjusted to minimize label-to-label cross-linking in all cases (with or without amines). In order to prevent possible inter-pigment bridging, acylating reagents such as acetic anhydride may be used to convert amines to carboxyl groups (in the case of acetic anhydride) or other groups non-reactive with the NHS such as thiols (e.g., SATA). The label must have some property that allows it to be monitored once coupled to one half of a specific binding pair. This could be fluorescence, chromogenicity, radioactivity, enzyme activity, physical density, etc. For convenience, activated labels may be referred to as “pigments,” but any detectable moiety that can be coupled via NHS chemistry may be used, regardless of light absorption. Typical labels include, but are not limited to, those listed below:

- phycobiliproteins (e.g., allophycocyanin, phycocyanin, phycoerythrin, phycoerythrocyanin, CryptoFluor™ dyes), subunits of the phycobiliproteins (e.g., alpha, beta and gamma subunits of phycoerythrin),
- phycobilisomes (cyanobacterial or red algal), including phycobilisome subcomplexes (rods and core),
- stabilized phycobilisomes, including stabilized phycobilisome subcomplexes (rods and core) or chemically stabilized phycobilisomes, such as those isolated from *Porphyridium cruentum* or *Arthrospira platensis* (e.g., PBXL-1 or PBXL-3, respectively), or tandem dyes containing these chemically stabilized phycobilisomes and Cy 5.5 (e.g., PBXL-2 or PBXL-4, respectively),
- enzymes (horse-radish peroxidase, alkaline phosphatase, DNA polymerase, RNA polymerase),
- latex beads (e.g., natural, dyed, activated),
- nucleic acids (e.g., RNA, DNA, PNA),
- modified nucleic acids (e.g., methylated, biotinylated, amine terminated),
- agarose beads (e.g., Sepharose™, Sephadex™),
- activated glass beads (e.g., modified CPG beads),
- magnetic beads (e.g., BioMag™),

- Lanthanide containing chelates, such as cryptates (e.g., europium, terbium), modified to contain free carboxyl groups or free amines,
- Organic dyes with free amine – such as amine containing aminofluorescein derivatives (e.g. fluorescein-5-thiosemicarbazole, 5-(((2-(Carbohyazino)methyl)thio)acetyl)-aminofluorescein, aminofluorescein) or rhodamine.
- recombinant or native protein fluors, such as Green Fluorescent Protein, Red Fluorescent Protein, Blue Fluorescent Protein and Yellow Fluorescent Protein.

Types of NHS –

- N-hydroxysuccinimide
- Sulfo-N-hydroxysuccinimide
- Water soluble NHS analogs

Types of water soluble carbodiimides –

- [EDAC] 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
- [CMC] 1-cyclohexyl-3-(2-morpholino-4-ethyl)-carbodiimide
- [DCC] dicyclohexyl carbodiimide
- [DIC] diisopropyl carbodiimide

Other possible cross-linking agents –

- [Woodward's Reagent K] N-ethyl-3-phenylisoxaxolium-3'-sulfonate
- [CDI] N,N'-carbonyldiimidazole

Methods of preparing reactive powder –

The reagents are dried in a sequential manner to separate the reactants from each other while maintaining the proper environment (e.g., pH) that maintains the compounds in the best form possible. For example, the label is added in aqueous form, frozen in liquid nitrogen, then the NHS is put in on top of this and instantly frozen, then the EDAC is added and instantly frozen. This entire construct is freeze-dried and the resulting tube stored under desiccation until needed. Alternative procedures for preparing the powder containing the label and other necessary reactants include:

- Freeze-drying/temporal separation of phases – The liquids are added and frozen sequentially, thereby separating the different pHs and reagents as frozen parts that do not mix. Then the whole thing is freeze-dried. (actual)
- Reagent stock solutions are frozen independently, freeze-dried and then reduced to a fine powder in a moisture-free environment. This is then added either separately to tubes or combined in proper proportion with the other reagents prior to dispensing into tubes for use.
- Dry chemicals are dispensed into tubes as single components, rather than being freeze-dried sequentially. They would then be mixed on addition of water to start the activation of the label. After a suitable incubation period, the compound (amine containing) would be added to react with the carbodiimide activated carboxyl. The resultant material is then dispensed in the proper weights to the reaction tubes.
- Dry chemicals are mixed to make the buffer then dispensed to the reaction chamber. Dry NHS and carbodiimide are added to the reaction mixture in proper proportion. All are sealed in a moisture free environment, preferably under vacuum until use. (prophetic)

The order of additions is not relevant to the outcome using the above protocol. It is important to make sure that the materials are rapidly frozen and do not significantly thaw the preceding layer. This can be accomplished by maintaining very cold (liquid nitrogen or dry ice) temperatures for the tube getting the liquid and using very cold solutions for the additions. It is most simple to add materials with the largest volumes first, then add the smaller volumes. The sides of the tubes can be used for implementing freezing prior to having the layers meet.

The materials could be pre-blended as freeze-dried or flash dried powders instead of layering as described above. In this case it will be harder to make the smaller tubes because such small amounts of material will be added to each tube. However, once blended, an automated dispenser could weigh materials into tubes in a very defined manner.

Kit Form

In a preferred mode, the reactive powder containing a detectable label for coupling to a desired target moiety is provided in a kit comprising N-

hydroxysulfosuccinimide (sulfo-NHS), a water-soluble carbodiimide (e.g. EDAC) and a label containing an amine or carboxyl moiety, these components being in a dry form suitable for rehydration at pH ranging from 6.0 to 8.0. A typical kit might contain:

5 Kit 1:

- Vial(s) containing powdered NHS, carbodiimide and label, preferably with dessicant pack(s) included in the packaging
- Vial(s) containing stop reagent
- Column(s) for separation of conjugate from unused label and stop reagent
- 10 – Bottle(s) containing dry powdered buffer for the loading and elution of conjugate (may be more than one depending on separation method used)

Kit 2:

- Vial(s) containing powdered NHS, carbodiimide and label, preferably with dessicant pack(s) included in the packaging

- 15 – Vial(s) containing stop reagent

Kit 3:

Vials containing the powdered NHS, carbodiimide and label, preferably with dessicant pack included in the packaging. Set for multiple labelings.

Production of labeled conjugates –

- 20 The dry mix of unreacted label, NHS, and carbodiimide is rehydrated for reaction with the target moiety (typically one member of a specific binding pair) to conjugate the label to the target moiety.

Types of specific binding partners –

- 25 The mixing of separate materials in such a manner that they are not reacted until addition of a final “target” component constitutes a composition of matter that is very general and can be applied to phycobiliproteins, PBXL™ dyes, enzymes or literally any carboxyl-containing label. In addition, many organic dyes can be modified to contain a carboxyl using standard organic chemistry. For example, phosgene can be used, in the presence of Friedel-Crafts catalysts, to introduce a
- 30 carboxyl group to aryl ring structures. March 1985 *J. Advanced Organic Chemistry*.

Suitable target moieties include, but are not limited to: receptors, aptamers, nucleic acids, modified nucleic acids, antibodies (IgG, IgA, IgM, Fc fragment, Fab fragment, F(ab')₂ fragment), ligands, pore forming compounds, lectins, peptides, cellular extracts, mixtures of molecules, synthetic antibodies and plastic antibodies and combinatorially produced materials containing free carboxyl groups or free amines that could provide reactive sites.

In one mode of the present invention, a freeze-dried mix of reagents is provided in a small tube, and the user adds the target molecule of interest either directly or after a short preincubation to get the best activation of the proteins, these are incubated for between 30 minutes and overnight then a quenching reagent is added. The conjugate can be used as is or purified over a gel permeation column. The freeze-dried mix may be provided in small vials for 1 mg conjugations.

Process Parameters

The sequential addition of reagents and sequestration of each in an inert state gives one the ability to make conjugates in a one step procedure. However, since the reaction does occur simultaneously upon rehydration, certain limitations are imposed on conjugation conditions, such as buffers (particularly pH), offered molar ratio (of various reactants as added to the reaction mixture), and the time of the reaction (both between the two partners (i.e. antibody to enzyme) and between sulfo-NHS and EDAC).

Experiments were done to find an appropriate pH for the optimal labeling. Since EDAC is more reactive at acidic pH's and sulfo-NHS is more reactive at more basic pH's there is a fine pH range (preferably pH 6.8 -7.4) for an effective conjugation. Experiments done at pH 6.0, in which EDAC is very reactive and Sulfo-NHS is unreactive, show that no conjugate is formed between APC and streptavidin under these conditions.

The offered molar ratio of protein to binding partner (i.e., label to target) will preferably be experimentally optimized for each set of conjugation partners. For example, preferred ratios for PBXL dyes to SA (1:25) differ from that of APC to SA (1.2:1). Another example is the conjugation of PBXL-3 to rabbit IgG which used an offered ratio of 20 IgG's to 1 PBXL-3 molecule.

The time of the reaction may be optimized. Overnight labeling is more efficient than 2 hour labeling times for APC conjugation to SA. However, 2 hour labeling is more convenient for most researchers.

The time of the reaction between sulfo-NHS and EDAC is important before the addition of binding partner to the rehydrated dye complex. Some of the dyes (labels) are known to rehydrate at different speeds. However, the short lifetimes of the EDAC at near neutral pH requires that the labels rehydrate or at least provide fairly homogeneous solutions promptly to allow even activation and prevent cross-linking of labels to each other.

EXAMPLES

In order to facilitate a more complete understanding of the invention, a number of Examples are provided below. However, the scope of the invention is not limited to specific embodiments disclosed in these Examples, which are for purposes of illustration only.

Example 1. Conjugation of phycoerythrin to streptavidin via 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide (EDAC) / N-hydroysulfosuccinimide (Sulfo-NHS) either directly (Standard Simultaneous Method) or from a freeze-dried reagent (Sequential Freezing Method).

Method: Two procedures for producing conjugates were performed according to the protocols outlined below. In the first procedure (the Standard Simultaneous Method or Standard Method) phycoerythrin (PE) was conjugated with streptavidin (SA) by mixing the two proteins (PE & SA) with EDAC and Sulfo-NHS simultaneously in buffer. The mixture was incubated at room temperature for 2 h to provide the conjugate. In the second procedure (the Sequential Freezing or Invention Method), PE + D-(+)-trehalose, EDAC, and sulfo-NHS solutions of specified content were flash frozen sequentially to prevent interaction of the chemicals, then freeze-dried. After being freeze-dried, the freeze-dried material was resuspended in streptavidin-containing phosphate buffer. The reactants were allowed to react at room temperature for at least 2 h. The resulting conjugate was purified by gel filtration.

The concentration and differential binding of conjugates were determined and are reported in the data table following the detailed protocol description below.

Standard Simultaneous Method – B-phycoerythrin (B-PE) was dialyzed against 1 L of 100 mM of sodium phosphate containing 0.05% sodium azide (pH = 6.8). This buffer was changed once every hour for 3 h, then the concentration of B-PE was determined by using its extinction coefficient. Streptavidin was then added to an approximately 3 mg/mL B-PE solution at a ratio of 2 to 1 (B-PE/SA). 1 M EDAC was then prepared in the same buffer used above and added into the reaction mixture to obtain a final concentration of 0.05 M EDAC. Then 0.1 M sulfo-NHS solution was prepared using the same buffer as above. Sulfo-NHS was added into the reaction mixture to obtain a final concentration of 0.005 M sulfo-NHS. The reaction was run at room temperature for 2 h. Then the conjugate was purified over SEPHADEX 300 (AMERSHAM PHARMACIA BIOTECH) using 100 mM sodium phosphate, 150 mM NaCl, and 0.05% sodium azide (pH 7.2) as the running buffer.

Sequential Freezing Method – B-PE was dialyzed against 1 L of 100 mM of sodium phosphate containing 0.05% sodium azide (pH 6.8) as above. This buffer was changed once every hour for 3 h. The B-PE concentration was determined by its extinction coefficient. D-(+)-trehalose powder was added into 1 mL of a 3 mg/mL B-PE solution to obtain a final concentration of 0.1 M trehalose. The mixture was vortexed until the powder was dissolved then flash frozen in liquid nitrogen in 1 mL aliquots in microcentrifuge tubes. Then 1 M EDAC and 0.1 M of sulfo-NHS stock solutions were prepared in the same buffer used above. EDAC stock was layered onto the frozen reagent containing the dye in such a volume to obtain a final concentration of 0.05 M EDAC when reconstituted to 1 mL and flash frozen. The sulfo-NHS was added into the above frozen reagents in such a volume to obtain a final concentration of 0.005 M sulfo-NHS in 1 mL final volume and flash frozen. The order of sequential freezing is not critical; however, the rapid freezing of reagents is critical to both maintain the activity of the agent being added, as well as to prevent interaction of the reagents before the rehydration step. The frozen reagents were then freeze-dried overnight. The next day 1 mL of a solution containing SA in

distilled water was prepared such that a 2/1 molar ratio of B-PE to SA will be produced on adding it to the tube. The freeze-dried mixture was resuspended in the 1 mL of SA solution and allowed to dissolve. The reaction was run at room temperature for 2 h then stored overnight at 4°C. The conjugate was purified over
5 SEPHADEX 300 (AMERSHAM PHARMACIA BIOTECH) using 100 mM sodium phosphate, 150 mM NaCl, and 0.05% sodium azide (pH 7.2) as the running buffer.

Assay of Differential Binding. A black 96 well MICROTITER plate (DYNEX LABORATORIES) was passively coated with 100 µL per well of 100 µg/mL
10 Biotinated BSA at 37°C for 4 h. Plates were washed 5 times with single strength PBS buffer (10 mM sodium phosphate (pH 7.0), 150 mM sodium chloride, and 0.05% sodium azide) at 200 µL per well. The plates were then blocked with 100 µL per well of MBB blocking buffer (1.5% BSA, 1% casein, 0.5% gelatin and 0.1% Tween 20 diluted to half strength with PBS at RT for 2 h. After blocking, the plates
15 were washed 5 times with 200 µL per well of 1x PBS. Conjugates were mixed in the indicated concentrations with 100 ng biotin/100 µL or without biotin in 100 mM of sodium phosphate containing 0.05% sodium azide (pH = 6.8) buffer and allowed to preincubate for 20 min at room temperature. Then 100 µL of sample (with or without competitive biotin added) was added to the wells of the BSA-biotin
20 precoated plates. These were allowed to react for 1 h at room temperature. Plates were then washed three times with 100 mM sodium phosphate, 150 mM NaCl, 0.05% NaN₃ (pH 7.2) with 200 µL per well for each wash. The wet plates were read on a FLUOROLITE 1000 plate reader (DYNEX LABORATORIES) using a 550 nm excitation and 590 nm emission filter set.

25

Effect of target protein to dye ratio (F/P) on specific binding. In this experiment the fluorescent dye to target protein ratio (F/P) was varied for the freeze-dried samples to see if better conjugates would be produced. To the freeze-dried samples, 0.5 M trehalose was added prior to freeze-drying as a cryoprotective agent in 100 mM
30 sodium phosphate (pH 6.8) buffer. Freeze-drying was carried out in the first experiments for 16 h. The amount of EDAC was 0.05 M and the amount of sulfo-

NHS was 0.005 for both the Sequential Freezing Method and Standard Simultaneous Method produced conjugates. The materials were used immediately after preparation. The assay was carried out at room temperature for 2 h then the samples were stored overnight at 4°C prior to the binding assay.

- 5 From the data, the not yet optimized conjugation works better in the Standard Simultaneous Method conjugate but the Sequential Freezing Method seems to work relatively well ($\geq 78\%$ differential binding) without further optimization of reagents. However, the data using an F/P ratio of 2 gave better differential binding than that at 3 for the freeze-dried materials.

10

Treatment	Conjugate ($\mu\text{g/mL}$)	- biotin	+ biotin	%Differential Binding
Liquid F/P ratio = 3	10	3506	116	97
	5	2327	105	95
	2.5	1100	104	91
	0.25	466	102	78
Freeze-Dried F/P ratio = 3	10	1858	403	78
	5	730	415	43
	2.5	427	435	-2
	0.25	405	399	1
Freeze-Dried F/P ratio = 2	10	nd	nd	nd
	5	1688	157	91
	2.5	649	163	75
	0.25	176	157	11

Example 2. Effect of longer freeze-drying time on conjugate performance using the Sequential Freezing Method.

- 15 In an effort to more closely link performance of the freeze-dried format to liquid materials, a more extensive and exhaustive freeze-drying was carried out in this experiment (64 h versus 16 h) to assure that all liquid was removed from the material. Only two conjugate concentrations were used (10 and 5 $\mu\text{g/mL}$) and an F/P ratio of 2 was used for all experiments. Otherwise, all conditions were as described in Example 1. No difference was observed between using the dyes for conjugation immediately
- 20 after freeze-drying or after storage at -20°C for one week. The differential binding achieved equaled that observed previously for the Standard Simultaneous Method

conjugation procedures. It appears that complete drying is critical for the proper performance of these reagents.

Treatment	Conjugate ($\mu\text{g/mL}$)	- biotin (cps)	+ biotin (cps)	% Differential Binding
Freeze-Dried	10	2062	82	96%
F/P Ratio = 2	5	1085	63	94%
Used Immediately				
Freeze-Dried	10	1855	74	96%
F/P Ratio = 2	5	1173	64	95%
Stored 1 week				

5 **Example 3. Effect of pH on conjugates produced from sequential freezing/freeze-dried R-PE activated material.**

To determine the optimal range of values for conjugate production from this format, R-PE conjugates to streptavidin were produced as described in Example 2 for B-PE
 10 except the 100 mM sodium phosphate buffer was adjusted to different pH values between 6.8 and 7.4 and quenched at 0.1 M lysine after the 2 h reaction at room temperature.

All dyes were offered at a F/P ratio of 2 and reagents used for conjugation
 15 immediately after freeze-drying. At the three concentrations of conjugate applied there was little difference in the differential binding observed at these different pH values. At pH 6.8 the best data was achieved but this difference was not substantially better than pH 7.4 and in fact all would probably deliver adequate performance as conjugation reagents.

pH	Conjugate ($\mu\text{g/mL}$)	- Biotin (cps)	+ Biotin (cps)	% Differential Binding
6.8	10	1975	75	96
	5	1159	73	94
	2.5	513	74	86
7.0	10	1840	74	96
	5	1083	70	94
	2.5	383	77	80
7.2	10	1755	76	96

	5	555	68	88
	2.5	285	70	75
7.4	10	1633	72	96
	5	736	64	91
	2.5	254	68	73

Example 4. Functional stability of freeze-dried reagents on storage at -20°C.

The need for stable product is obvious for this invention. A short-term study to determine if the products rapidly degraded was performed using B-PE made and freeze-dried as described in Example 3 except that 0.1 M trehalose was used in the freezing medium. Reactions were performed at pH 6.8 and not quenched. At least up to three weeks of storage seemed to have little or even a beneficial effect on the conjugates produced with these reagents.

Storage Time (weeks)	Conjugate (µg/mL)	- Biotin (cps)	+ Biotin (cps)	% Differential Binding
0	10	2023	209	90
	5	1206	185	85
1	10	902	77	91
	5	264	72	73
2	10	2920	63	98
	5	1579	61	96
	2.5	474	58	88
3	10	2360	57	98
	5	990	57	94
	2.5	394	56	86

Example 5. Conjugation of chemically stabilized phycobilisomes (PBXL-3; MARTEK BIOSCIENCES) to streptavidin using the sulfo-NHS/EDAC/D-(+)-trehalose Sequential Freezing Method.

The Sequential Freezing Method (Invention Method) was compared to the Standard Simultaneous Method for making PBXL-3 labeled streptavidin conjugates. In the Standard Simultaneous Method, PBXL-3 was combined with streptavidin (SA), EDAC and Sulfo-NHS in buffer and reacted simultaneously in a manner analogous to literature methods. The mixture was incubated at room temperature for 2 h. In the Sequential Freezing Method, the following reagents were sequentially freeze-dried:

PBXL-3 in 100 mM sodium phosphate plus D-(+)-Trehalose, 1 M EDAC and 0.1 M sulfo-NHS in defined volumes. The frozen materials were freeze-dried overnight, then the dried powder was resuspended in streptavidin-containing very low concentration phosphate buffer. This was allowed to react for 2 h at room temperature. The conjugates were then purified by gel filtration over SEPHAROSE 6B. The differential binding of conjugates was determined and compared for performance of the conjugation formats.

Protocol:

Standard Simultaneous Method – PBXL-3 was dialyzed again 1 L of 100 mM of sodium phosphate (pH 7.4) with buffer changes once an hour for 3h. The concentration of PBXL-3 was determined by its absorbance at 620 nm (5 Au/mg PBXL-3). Streptavidin was added to the PBXL-3 solution at an F/P ratio of 0.4 or 25 SA per PBXL-3 complex. A 1 M stock of EDAC was prepared in the same buffer used above and added into the reaction mixture to obtain a final concentration of 0.05 M. A 0.1 M of Sulfo-NHS solution was prepared using the same buffer as above and added into the reaction mixture to obtain a final concentration of 0.005 M. This was reacted at room temperature for 2h. The conjugate was purified over SEPHAROSE CL6B (AMERSHAM PHARMACIA BIOTECH) using 100 mM sodium phosphate, 150 mM NaCl, and 0.05% sodium azide (pH 7.2) as the running buffer.

Sequential Freezing Method – PBXL-3 was dialyzed against 1 L of 100 mM of sodium phosphate (pH 7.4) and the buffer was changed once every hour for 3 h. The concentration of PBXL-3 was determined by its absorbance at 620 nm (5 Au/1 mg protein). This was mixed (by vortexing) with D-(+)-Trehalose powder to a final concentration of 0.5 M then aliquoted into microcentrifuge tubes and flash frozen in liquid nitrogen or on a methanol/dry ice bath. A 1 M EDAC stock solution was made in the same buffer used above and added, in such a volume to deliver (on mixing of all reagents) a final concentration of 0.05 M, on top of the frozen material while still under liquid nitrogen temperatures to achieve nearly instant freezing of the added materials. A 0.1 M of sulfo-NHS solution was made using the same buffer as

above and added, in such a volume to deliver on mixing of all reagents a final concentration of 0.005 M, on top of the previously frozen reagents still under liquid nitrogen temperatures to achieve nearly instant freezing of the added materials. This was freeze-dried overnight. A solution containing SA in various molar ratios was prepared using the same buffer as above. This SA solution was used to resuspend the freeze-dried mixture to the volume of solution before the freeze-drying step (to keep all reagents at defined concentrations). The resuspended reagents and SA were reacted together at room temperature for 2 h. The resulting conjugate as purified over SEPHAROSE CL6B (AMERSHAM PHARMACIA) using 100 mM sodium phosphate, 150 mM NaCl and 0.05% sodium azide (pH 7.2) as the running buffer.

Differential binding assay. A black 96 well MICROTITER plate (DYNEX LABORATORIES) was passively coated with 100 μ L per well of 100 μ g/mL Biotinylated BSA at 37°C for 4 h. Plates were washed five times with 1 x PBS and blocked with MBB blocking buffer as previously described. Plates were washed five times with 200 μ L per well of 1 x PBS. Conjugate with or without 100 ng biotin/100 μ L were mixed together as indicated in the table in Assay Buffer and preincubated for 20 min before adding into wells. Preincubated materials were added at 100 μ L/well and allowed to react at room temperature for 1 h. Plates were washed three times with 200 μ L per well 100 mM sodium phosphate (pH 7.2), 150 mM NaCl, 0.05% NaN₃ buffer. Plates were then read on the FLUOROLITE 1000 (DYNEX LABORATORIES) using a 590 nm filter for excitation and a 660 nm filter for emission, the voltage was set at 7.7V.

Treatment*	Conjugate μ g/mL	-biotin (cps)	+biotin (cps)	% Differential Binding
Simultaneous	50	over	30	nd
PBXL-3/SA ratio = 25	25	3056	15	100
Liquid Reagents	12.5	1594	11	99
	6.25	642	8	99
Sequential	36	903	17	98
PBXL-3/SA ratio = 25	18	115	14	88
Freeze-Dried Reagents	9	10	10	0
	4.5	8	8	0

*Simultaneous = Standard Simultaneous Method; Sequential = Sequential Freezing Method or Invention Method

Example 6. Comparison of Sequential Freezing Method to the Standard Simultaneous Method for EDAC/sulfo-NHS cross-linking and to another standard cross-linking method, SMCC/SATA.

Another set of experiments was done comparing conjugates made by the two sulfo-NHS/EDAC methods (Sequential Freezing and Standard Simultaneous Methods) as described in Example 5 and a standard SMCC/SATA conjugation method. Similar performance was provided by all of these methods.

Simultaneous Sulfo-NHS/EDAC			Sequential Sulfo-NHS/EDAC		SMCC/SATA	
Conj. μg/mL	-Biotin/ +Biotin	%Δ Binding	-Biotin/ +Biotin	%Δ Binding	-Biotin/ +Biotin	%Δ Binding
50	729/4	99%	280/2	99%	451/6	99%
25	516/3	99%	42/2	95%	194/4	99%

*Simultaneous = Standard Simultaneous Method; Sequential = Sequential Freezing Method or Invention Method

Example 7. Conjugation of allophycocyanin (APC) to streptavidin via the sulfo-NHS/EDAC Sequential Freezing Method (Invention) compared to Standard Simultaneous Method.

Method: The Invention Method was compared to a Standard Simultaneous Method for the ability to produce functional APC labeled streptavidin conjugates. In the Standard Simultaneous Method, APC was combined with streptavidin (SA), EDAC and sulfo-NHS simultaneously. Then the mixture was incubated at room temperature for 2 h to form a conjugate and the conjugate purified by gel permeation. In the Sequential Freezing Method, APC was mixed with D-(+)-trehalose and frozen. A specific amount of EDAC solution was then layered on top of the frozen dye and flash frozen, then a solution of sulfo-NHS was layered on top of the frozen reagents and flash frozen. The unmixed (due to flash freezing), frozen reagents were freeze-dried overnight. The dry reagents were resuspended in streptavidin-containing low

phosphate buffer and reacted at room temperature at least 2 h. The resulting conjugates were purified by gel filtration. The concentration and differential binding of conjugates were determined and compared for their ability to bind biotin specifically.

5

Protocol:

Standard Simultaneous Method – APC was dialyzed against 1 L of 100 mM of sodium phosphate containing 0.05% sodium azide (pH 7.2) changing the buffer once every hour for 3 h. APC concentration was determined using its extinction coefficient. Streptavidin was added to a 3-5 mg/mL APC solution at a ratio 1.2 to 1 of F/P (fluor to target protein). A 1 M EDAC solution was prepared in the same buffer used above then added to the reaction mixture to obtain a final concentration of 0.05 M EDAC. A 0.1 M stock solution of sulfo-NHS was made in the same buffer as above then added into the reaction mixture to obtain a final concentration of 0.005 M sulfo-NHS. The reaction mixture was incubated at room temperature at least 2 h. The resulting conjugate was purified over a SEPHADEX 300 column (AMERSHAM PHARMACIA) using 100 mM sodium phosphate, 150 mM NaCl, 0.05% sodium azide (pH 7.2) as the running buffer.

Sequential Freezing Method – APC was dialyzed and quantitated as above. D-(+)-Trehalose powder was added to a 3-5 mg/mL APC solution to obtain a final concentration of 0.5 M trehalose. The mixture was vortexed mixed until the powder was dissolved. This was aliquoted and flash frozen in liquid nitrogen or a dry ice/methanol bath. Then 1 M of EDAC and 0.1 M sulfo-NHS stocks were prepared as described above. Aliquots of EDAC solution were layered on top of the frozen pigment solution, in such a volume to deliver a final concentration of 0.05 M on resuspension, while the tubes were still in the freezing solution to provide flash freezing of the EDAC addition. The sulfo-NHS stock was added, in such a volume to obtain a final concentration of 0.005 M, on top of the reagents already frozen in the tube while still in the freezing solution to provide rapid freezing of the sulfo-NHS reagent. Frozen reagents were then freeze-dried overnight. An aqueous SA solution

that will deliver a F/P ratio of 1.2/1 was made then used to resuspend the freeze-dried reagents to 1 mL. These reacted at room temperature for 2 h then were stored overnight at 4°C. The resulting conjugate was purified as described above.

- 5 Differential binding assay – Done as previously described for PBXL-3 using the 590 nm excitation and 660 nm emission filter set.

The Sequential Freezing Method for NHS/EDAC mediated cross-linking described in this invention compares very well to the simultaneous mixing method in giving
10 consistently high differential binding with the APC labeled streptavidin to BSA biotin plates in the presence or absence of competing biotin. Trehalose does not seem to be necessary for storage of up to one week at -20° C.

Treatment*	Conjugate (µg/mL)	-biotin (cps)	+biotin (cps)	%Differential Binding
Simultaneous	10	4013	16	100
Liquid	5	3894	11	100
Simultaneous	10	3638	14	100
Liquid	5	2712	10	100
Sequential	10	2198	11	99.5
Freeze-dried	5	2039	10	99.5
No trehalose	2.5	1273	10	99.2
	0.25	114	9	92
Sequential	10	2349	11	99.5
Freeze-dried	5	2146	9	99.6
0.1 M trehalose	2.5	998	10	99
	0.25	42	9	78
Sequential	10	3182	19	99.4
Freeze-dried	5	2842	13	99.5
No trehalose	2.5	2225	13	99.4
1 week storage	0.25	244	11	99.5

*Simultaneous = Standard Simultaneous Method; Sequential = Sequential Freezing Method or Invention Method

Example 8. Conjugation of PBXL-3 (MARTEK BIOSCIENCES) to Goat anti-Rabbit IgG using via the sulfo-NHS/EDAC Sequential Freezing Method (Invention).

Method and Protocol: In this experiment PBXL-3 was dialyzed and quantitated as above. D-(+)-Trehalose powder was added to a 3 mg/mL PBXL-3 solution to obtain a final concentration of 0.5 M trehalose. The mixture was vortexed mixed until the powder was dissolved. This was aliquoted and flash frozen in liquid nitrogen bath.

5 Then 1 M of EDAC and 0.1 M sulfo-NHS stocks were prepared as described above. Aliquots of EDAC were layered on top of the frozen pigment solution, in such a volume to deliver a final concentration of 0.05 M on resuspension (1 mL), while the tubes were still in the freezing solution to provide flash freezing of the EDAC addition. The sulfo-NHS stock was added, in such a volume to obtain a final
10 concentration of 0.005 M, on top of the reagents already frozen in the tube while still in the freezing solution to provide rapid freezing of the sulfo-NHS reagent. Frozen reagents were then freeze-dried overnight. An aqueous Goat anti-Rabbit IgG solution that will offer a F/P ratio of 2/1 was made then used to resuspend the freeze-dried reagents to 1 mL. These reacted at room temperature for 2 h then were stored
15 overnight at 4°C. The resulting conjugate was purified as described above.

Differential binding assay – Done as previously described for PBXL-3 using the 590 nm excitation and 660 nm emission filter set.

20 This sequential method although not optimized in this example, illustrates that commercially available antibodies can be attached to PBXL dyes. These conjugates then could be used in function binding assays.

Treatment*	Conjugate μg/mL	-Rabbit IgG (cps)	+Rabbit IgG (cps)	% Differential Binding
Sequential	50.00	170	38	77.6
	25.00	70	28	60.0
	12.50	58	23	60.3
	6.25	42	22	47.6

Sequential = Sequential Freezing Method or Invention Method

Example 9. Determination of the optimal time for addition of target protein (streptavidin) to resuspended freeze-dried reagents using the sulfo-NHS/EDAC chemistry formatted as the Sequential Freezing Method.

5 The data in Figure 2 illustrate an example of a time course used to determine when is the optimal time to add the conjugation partner in the Sequential Freezing Method. An essential question for the ease of use of this method was to determine if it could be made as a one step (add the protein in solution and you are done) versus rehydrate and add at some optimal time later. This was done mostly to see how
10 much better the conjugates could be produced since it was thought that unrestricted cross-linking of the wrong reagents might occur if you did not first activate the label before adding the binding partner.

Differential binding assay – The binding assay was carried out as previously described
15 for PBXL-3 using the 590 nm excitation and 660 nm emission filter set. Figure 2 illustrates the importance of adding the binding partner within a half hour of rehydrating the sequentially frozen sample. Conjugation efficiency is greatly affected by having the chemical reactants and the PBXL-3 in solution for sustained lengths of time prior to addition of the binding partner. Interestingly, there is not a large
20 increase in functional effectiveness between adding the binding partner after 30 min (when the dye would be fully activated) and adding the binding partner immediately. This is unexpected and provides a very simple format for the Sequential Freezing Method (rehydrate with an aqueous suspension of the target protein, incubate, purify and use).

25 Because solution phase chemical reactants become ineffective the longer one waits prior to addition of binding partner, formats that store liquid materials would not be suitable for this type of reaction. After twenty-four hours, the reactive groups are no longer functional. This data illustrates the utility for spatial or temporal separation
30 between the NHS, EDAC and PBXL-3 provided by the Sequential Freezing Method in providing a simple and rapid method for making useful conjugates.

Example 10. Stability of PBXL-3 labeled streptavidin produced using the Sequential Freezing Method.

- 5 The stability of a PBXL-3 labeled streptavidin conjugate was evaluated at several time points to determine if adequate stability was present with labeled proteins produced with the Sequential Freezing Method. The binding assay was done as previously described except that a biotin dose response curve was generated at each time point to better evaluate the stability of these conjugates. Figure 3 shows three
- 10 biotin dose response curves corresponding to three samples made from one run of the Sequential Freezing Method that were rehydrated over the course of one month (1 day, 7 days, 28 days) and conjugated to the same lot of streptavidin on the day of rehydration. The three virtually over lapping free biotin dose response curves indicate that the labeling of the PBXL-3 to streptavidin is fairly consistent throughout
- 15 one month's storage time of the freeze-dried reagents described by this invention.

CLAIMS:

1. A single vessel containing N-hydroxysuccinimide (NHS), a water-soluble carbodiimide and a label containing an amine or a carboxyl moiety, these components being in a single vessel in dry form suitable for rehydration at pH about 7.
2. A method for conjugating label to target moiety comprising:
 - a placing a label, NHS, and a carbodiimide in a container such that the three components are sequestered from reaction with each other;
 - b storing the components in dry form; and
 - c hydrating the components to initiate reaction between them, wherein a target moiety is conjugated to the label.
3. The method of claim 2, wherein the target is added at the time the components are hydrated.
4. The method of claim 2, wherein the target is added subsequent to hydrating the components.
5. A method of conjugating label to target moiety, comprising:
 - a derivatizing a label by reaction with one functionality of a heterofunctional reagent;
 - b placing derivatized label in a container with an activating reagent specific for activation of the unreacted functionality of the heterofunctional reagent or its reaction partner such that the derivatized label and activating reagent are sequestered from reaction with each other;
 - c hydrating label and activating reagent;
 - d removing the activating reagent in the presence of a target moiety, whereby the target moiety is conjugated to the label.
6. A method of conjugating label to target moiety according to claim 5, comprising:
 - a derivatizing a label containing primary or secondary amines with a maleimide functionality;
 - b placing maleimide derivatized label in a container with a reductant in dry form;

- c. hydrating label and reductant; and
- d. removing reductant in the presence of a target moiety, whereby the target moiety is conjugated to the label.

- 5 7. A single vessel containing a label derivatized with one functionality of a heterofunctional reagent and an activating reagent specific for activation of the unreacted functionality of the heterofunctional reagent or its reaction partner, these components being in a single vessel in dry form suitable for rehydration.

1/2




FIG. 1




FIG. 2

2/2




FIG. 3

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As the below named inventor, I hereby declare that:

My residence, post office address and citizenship is as stated below next to my name;

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

SIMPLE METHOD FOR LABELED CONJUGATE PRODUCTION

the specification of which: ☐ is attached hereto.

☒ was filed on:

January 22, 2000

as Application No.:

PCT/US00/01350

and was amended on:

(if applicable).

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56.

And I hereby authorize and request our agents, Brobeck, Phleger & Harrison LLP, whose address is set forth below, to insert above, the filing date and application number of said application when known.

Prior Foreign Application(s)

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Country	Application Number	Date of Filing (day, month, year)	Date of Issue (day, month, year)	Priority Claimed	
				Yes <input type="checkbox"/>	No <input type="checkbox"/>
				Yes <input type="checkbox"/>	No <input type="checkbox"/>

Prior Provisional Application(s)

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application Number	Date of Filing (day, month, year)
60/116,689	January 22, 1999

Prior United States Application(s)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Number	Date of Filing (day, month, year)	Status - Patented, Pending, Abandoned
PCT/US00/01350	January 22, 2000	pending


And I hereby appoint, both jointly and severally, as my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith the following attorneys, their registration numbers being listed after their names:

Rodger L. Tate, Registration No. 27,399; Anthony W. Shaw, Registration No. 30,104; Cono A. Carrano, Registration No. 39,623; Laurence H. Posorske, Registration No. 34,698; Robert A. King, Registration No. 42,738; Craig L. Puckett, Registration No. 43,023; and Trevor Q. Coddington, Registration No. 46,633.

All correspondence and telephone communications should be addressed to: Brobeck, Phleger & Harrison LLP; Intellectual Property Department; 1333 H Street, N.W.; Suite 800; Washington, DC 20005; telephone number (202) 220-6000; facsimile number (202) 220-5200, which is also the address, telephone and facsimile numbers of each of the above listed attorneys.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine and imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature



Date 12/4/01

Full Name of
First Inventor:

MORSEMAN
(Family Name)

John
(First Given Name)

P.
(Second Given Name)

Citizenship: United States

Residence: 9615 Rocksparkle Row, Columbia, MD 21045

MD

Post Office
Address: (Same as above)

Signature

Date _____

Full Name of

Second Inventor: ZENG
(Family Name)

Xiangfei
(First Given Name)

(Second Given Name)

Citizenship: China

Residence: 407 N.W. Kotrick Place, Beaverton, Oregon

Post Office
Address: (same as above)

Signature _____ Date _____

Full Name of First Inventor: **MORSEMAN** **John** **P.**
(Family Name) (First Given Name) (Second Given Name)

Citizenship: United States

Residence: 9615 Rocksparkle Row, Columbia, MD 21045

Post Office Address: (Same as above)

2W Signature Xiangfei Zeng Date 10/29/01

Full Name of Second Inventor: ZENG Xiangfei _____
(Family Name) (First Given Name) (Second Given Name)

Citizenship: China United states

Residence: 407 N.W. Kotrick Place, Beaverton, Oregon U.S.

Post Office Address: (same as above)